In our previous study, we demonstrated that in BRAF-mutant metastatic melanoma patients treated with a BRAF inhibitor, a higher expression of Y RNA-1 was associated with worse prognosis [58]. The gene discussed is BRAF; the disease is metastatic melanoma.